Disodium Phosphate Anhydrous, CAS# 7558-79-4, is a inorganic compound manufactured through chemical synthesis, available as white crystaline powder. Disodium Phosphate Anhydrous is widely used as food supplements. It is widely accepted as safe food additive in many countries.
No significant side effects reported. The only concern is prolonged using of phosphate salts may upset the balance of phosphates and other chemicals in the body.
Ingestion of Disodium Phosphate Anhydrous in large quantity may hurt our health, please follow the guideline of using Disodium Phosphate Anhydrous: MTDI 70 mg/kg body weight (as P)
Special groups refer to newborns, children, pregnant and any other applicable vulnerable groups.
There is no evidence that Disodium Phosphate Anhydrous could have any negative effects on these vulnerable groups. It should be safe to use Disodium Phosphate Anhydrous in food for newborns and pregnant. However, we still recommend consumers to consult professionals before using large quantity of Disodium Phosphate Anhydrous for long period in food for newborns or pregnant.
Generally recognized as safe(GRAS) is a FDA designation that a specific substance or ingredient is generally considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements. Disodium Phosphate Anhydrous is considered safe by FDA according to existing data and granted GRAS status.
No breaking news or public health crises reported about Disodium Phosphate Anhydrous reported up to now.
* Want to report news about this ingredient, please send email to firstname.lastname@example.org. Your knowledge can help us to uncover more truthes about food ingredients to customers.
1. Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. [J Ocul Pharmacol Ther. 2008 Jun]
Author: Hosseini K, Matsushima D, Johnson J, Widera G, Nyam K, Kim L, Xu Y, Yao Y, Cormier M.
2. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. [Int J Radiat Oncol Biol Phys. 2008 Mar 1]
Author: Nielsen T, Murata R, Maxwell RJ, Stødkilde-Jørgensen H, Ostergaard L, Horsman MR.
3. Anaphylaxis induced by intramuscular betamethasone disodium phosphate: reflections on a clinical case. [Int J Immunopathol Pharmacol. 2007 Apr-Jun]
Author: Ventura MT, Sanapo F, Calogiuri GF, Satriano F.
4. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. [Neoplasia. 2007 Feb]
Author: Ley CD, Horsman MR, Kristjansen PE.
5. Prognostic value of the disodium phosphate 32P uptake test in uveal melanoma: a long-term study. [Arch Ophthalmol. 2003 Oct]
Author: Overkleeft EN, Zuidervaart W, Hurks HM, Eilers PH, de Wolff-Rouendaal D, Jager MJ.